MetaVia Inc. announced that it will present new Phase 1 and pre-clinical data on DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors, at ObesityWeek® 2025, scheduled for November 4-7, 2025, in Atlanta, GA. The Phase 1 study demonstrated favorable safety and tolerability, as well as a pharmacokinetic profile supporting once-weekly dosing. Meaningful reductions in body weight and waist circumference were observed after four weeks of treatment. Additionally, in pre-clinical diet-induced obesity mouse models, DA-1726 achieved comparable weight loss to pemvidutide and showed superior lipid-lowering effects. Results from an extended Phase 1 cohort evaluating a higher 48 mg dose are expected later in 2025. The data have not yet been presented and are scheduled for release at the upcoming conference.